News LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.74 ^USD	-8.05%		-6.80%	+73.42%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	Mar. 20	GL
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	Mar. 20	AQ
LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)	Mar. 05	GL
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	Mar. 05	CI
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	Jan. 30	AQ
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25	MT
Sector Update: Health Care	Jan. 25	MT
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	Jan. 25	MT
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	Jan. 25	MT
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda	Jan. 25	DJ
Top Premarket Gainers	Jan. 25	MT
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®	Jan. 25	GL
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	Jan. 25	CI
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	Nov. 16	GL
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	GL
HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating	23-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Summary

Filters